405 related articles for article (PubMed ID: 26241880)
1. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness and monetary benefits of dabigatran in the prevention of arterial thromboembolism for patients with non-valvular atrial fibrillation in the Netherlands.
van Hulst M; Stevanovic J; Jacobs MS; Tieleman RG; Kappelhoff B; Postma MJ
J Med Econ; 2018 Jan; 21(1):38-46. PubMed ID: 28836865
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
[TBL] [Abstract][Full Text] [Related]
5. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
8. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
Chevalier J; Delaitre O; Hammès F; de Pouvourville G
Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.
Carles M; Brosa M; Souto JC; Garcia-Alamino JM; Guyatt G; Alonso-Coello P
BMC Health Serv Res; 2015 Jul; 15():289. PubMed ID: 26215871
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of the use of non-vitamin K oral anticoagulants in patients with atrial fibrillation on antiplatelet therapy: a modelling analysis using the healthcare system in the Netherlands.
Bennaghmouch N; de Veer AJWM; Mahmoodi BK; Jofre-Bonet M; Lip GYH; Bode K; Ten Berg JM
Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):127-135. PubMed ID: 30016398
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Wouters H; Thijs V; Annemans L
J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Gourzoulidis G; Kourlaba G; Kakisis J; Matsagkas M; Giannakoulas G; Gourgoulianis KI; Vassilakopoulos T; Maniadakis N
Clin Drug Investig; 2017 Sep; 37(9):833-844. PubMed ID: 28608312
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
17. A cost-analysis model for anticoagulant treatment in the hospital setting.
Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
[TBL] [Abstract][Full Text] [Related]
18. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
19. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
